A Retroprospective observational study was conducted on Covid-19-associated mucormycosis (CAM) patients who underwent surgery at our institute. A total of 175 patients who met the inclusion and exclusion criteria were included in our study The study aimed to correlate the Overall survival and disease-specific survival rates with sites of involvement in patients with Covid Associated Mucormycosis and develop a novel prognostic classification of Mucormycosis. At the end of 24 months, the overall survival rate was 73.1% which can be attributed to the early diagnosis, timely & aggressive intervention, and multidisciplinary management. The Disease-Specific Survival rates were 90.16% (55alive/61total) for Sinonasal Mucormycosis, 87% (41/47) for Rhinomaxillary Mucormycosis, 64.7% (22/34) for Rhinoorbital Mucormycosis and 45.45% (10/22) for Rhinocerebral Mucormycosis. A statistically significant difference was seen between the disease severity and outcome.